Pharma Mar (PHM.MC) Stock Price
Pharma Mar Price
Revenue has compounded at 5.8% per year over the past 19 years to 221.39 M EUR. Earnings per share have grown at 21.2% per year over the last 13 years. Pharma Mar's net margin stands at 33.9%, down from 40.4% several years earlier. Pharma Mar currently offers a dividend yield of about 1.12%. The payout ratio is around 18% of earnings. The dividend has grown at 15.5% per year over the past 18 years. Analysts set a median price target of 107.10 EUR, implying 50.0% above the current price. Of 13 analysts, 9 rate the stock a buy — an overall Buy consensus.
Pharma Mar stock price
Pharma Mar business model & stock analysis
Frequently asked questions about Pharma Mar
The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.
Pharma Mar SA is primarily active in the pharmaceutical industry.
The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.
Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.
Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.
Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.
Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.
Analysts currently set an average price target of 99.84 EUR for the Pharma Mar stock (median: 107.10 EUR), implying +39.8 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Pharma Mar stock: 9 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Pharma Mar to generate revenue of 212.28 M EUR and earnings per share of 1.84 EUR.
The Pharma Mar share (PHM.MC) is listed on 7 stock exchanges, including: London (0RC6.L), Frankfurt (PMRA.F), München (PMRA.MU), Düsseldorf (PMRA.DU), Madrid (PHM.MC).
Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.
The expected revenue of Pharma Mar is 212.28 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pharma Mar is 31.72 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pharma Mar is currently 38.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharma Mar stock.
The price-to-sales ratio (P/S) of Pharma Mar is currently 5.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharma Mar stock.
The Eulerpool Quality Score for Pharma Mar is 3/10.
The ISIN of Pharma Mar is ES0169501022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pharma Mar is A2P9YT. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pharma Mar is PHM.MC. The ticker symbol is used to trade Pharma Mar shares on the stock exchange.
Pharma Mar stock
Pharma Mar Peer Group
Pharma Mar Ticker
Pharma Mar FIGI
All fundamentals and in-depth analysis of Pharma Mar
Our stock analysis for Pharma Mar stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.